Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.
Serologic testing for hepatitis B surface antigen (HBsAg) is the primary way to identify persons with chronic hepatitis B virus (HBV) infection. Testing has been recommended previously for pregnant women, infants born to HBsAg-positive mothers, household contacts and sex partners of HBV-infected persons, persons born in countries with HBsAg prevalence of >/=8%, persons who are the source of blood or body fluid exposures that might warrant postexposure prophylaxis (e.g., needlestick injury to a health-care worker or sexual assault), and persons infected with human immunodeficiency virus. This report updates and expands previous CDC guidelines for HBsAg testing and includes new recommendations for public health evaluation and management for chronically infected persons and their contacts. Routine testing for HBsAg now is recommended for additional populations with HBsAg prevalence of >/=2%: persons born in geographic regions with HBsAg prevalence of >/=2%, men who have sex with men, and injection-drug users. Implementation of these recommendations will require expertise and resources to integrate HBsAg screening in prevention and care settings serving populations recommended for HBsAg testing. This report is intended to serve as a resource for public health officials, organizations, and health-care professionals involved in the development, delivery, and evaluation of prevention and clinical services.
Weinbaum
Cindy M
CM
Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 1600 Clifton Road, MS G-37, Atlanta GA 30333, USA. chw4@cdc.gov
Williams
Ian
I
Mast
Eric E
EE
Wang
Susan A
SA
Finelli
Lyn
L
Wasley
Annemarie
A
Neitzel
Stephanie M
SM
Ward
John W
JW
D000293:Adolescent; D000328:Adult; D002487:Centers for Disease Control and Prevention, U.S.; D002648:Child; D016358:Contact Tracing; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D006515:Hepatitis B virus / Q000472:pathogenicity / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008403:Mass Screening; D011159:Population Surveillance; D015995:Prevalence; D011634:Public Health; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines